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ABSTRACT  
High CIP2A protein levels at diagnosis of chronic myeloid leukaemia (CML) are predictive of disease 
progression in imatinib treated patients. It is not known whether this is true in patients treated with 
second generation tyrosine kinase inhibitors (2G TKI) from diagnosis, and whether 2G TKIs modulate 
the CIP2A pathway. Here, we show that patients with high diagnostic CIP2A levels who receive a 2G 
TKI do not progress, unlike those treated with imatinib (p=<0.0001). 2G TKIs induce more potent 
suppression of CIP2A and c-Myc than imatinib. The transcription factor E2F1 is elevated in high CIP2A 
patients and following 1 month of in vivo treatment 2G TKIs suppress E2F1 and reduce CIP2A; these 
effects are not seen with imatinib.  Silencing of CIP2A, c-Myc or E2F1 in K562 cells or CML CD34+ cells 
reactivates PP2A leading to BCR-ABL suppression. CIP2A increases proliferation and this is only 
reduced by 2G TKIs. Patients with high CIP2A levels should be offered 2G TKI treatment in preference 
to imatinib. 2G TKIs disrupt the CIP2A/c-Myc/E2F1 positive-feedback loop, leading to lower disease 
progression risk. The data supports the view that CIP2A inhibits PP2Ac, stabilising E2F1, creating a 
CIP2A/c-Myc/E2F1 positive-feedback loop which imatinib cannot overcome.  
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INTRODUCTION 
Chronic myeloid leukaemia (CML) is a malignant disease of the primitive haematological cell in which 
a reciprocal translocation between chromosomes 9 and 22 creates the fusion gene BCR-ABL1 which is 
the molecular hallmark of the disease.1 CML treatment has been significantly improved by the tyrosine 
kinase inhibitor (TKI) imatinib, but at least one-third of patients will eventually fail imatinib 
treatment2,3 and a significant proportion of these will progress towards blast crisis (BC), which is 
usually rapidly fatal.  
 
Impairment of PP2A activity by its negative regulators SET and cancerous inhibitor of PP2A (CIP2A) 
plays an important role in the pathogenesis and progression of CML.4,5 CIP2A protein is associated 
with increased proliferation in several human malignancies6-10 and its over-expression can cause 
cellular transformation.7,11 High levels are an adverse prognostic indicator in many malignancies 
including AML,12 breast,8, 13-15 bladder,16  cervical,17,18 and lung cancers.10,20,21 In CML, we have shown 
that high levels of CIP2A protein at chronic phase diagnosis is a strong prospective predictor of 
subsequent development of BC.5 CIP2A functions by preventing PP2A driven dephosphorylation of c-
Myc at residue serine 62, which results in stabilisation of c-Myc.2,7,9,15 SET also inhibits c-Myc 
degradation.22 c-Myc is essential for BCR-ABL mediated cellular transformation23 and is over-
expressed at transformation to BC.24 In CML, elevated levels of c-Myc may promote aneuploidy, 
contributing to disease progression.25,26 Furthermore, protein levels of c-Myc at diagnosis correlate 
with imatinib treatment response.5   
 
E2F1 is a transcription factor which is over-expressed in CML.27 E2F proteins are involved in cell cycle 
regulation by controlling genes required for cell-cycle progression at the G1/S checkpoint.28 E2F1 
transcriptionally regulates CIP2A8 and c-Myc.29 E2F1 activates cell cycle and over-expression of E2F1 
results in uncontrolled cellular proliferation.30 There is cross-talk between E2F transcription factors, 
as depletion of E2F1 has no effect and E2F1 deficient mouse embryos develop normally.31 E2F1 activity 
can be regulated by phosphorylation on residue serine 364, which is controlled by PP2A.32 When 
phosphorylated, E2F1 is stabilised and cannot be degraded. In addition to phosphorylation, E2F1 
transcriptional activity can be negatively regulated via the p53/p21/Rb pathway.8,32,33  
 
 
We have previously shown that patients with a high CIP2A protein level at diagnosis and treated with 
imatinib have a 100% actuarial risk of progressing to BC.5 However, the second generation TKIs (2G 
TKIs) dasatinib and nilotinib are now increasingly used for first-line CML treatment and both drugs 
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may have superior clinical outcomes compared to imatinib.34,35  It is not known whether high CIP2A 
levels confer a poor prognosis in patients treated with a 2G TKI at initial diagnosis or whether the 2G 
TKIs modulate the CIP2A pathway. In this study we assessed the clinical outcome of 74 patients treated 
with imatinib or a 2G TKI (dasatinib or nilotinib) in relation to their diagnostic CIP2A level. Here we 
confirm our earlier report that imatinib treated patients with high diagnostic CIP2A have a high risk of 
developing BC, in a larger cohort with longer follow up. We also report that in contrast, patients with 
high diagnostic CIP2A do not progress to BC if treated with a 2G TKI. We show that this benefit is 
because unlike imatinib, 2G TKIs suppress CIP2A, leading to decreased c-Myc and E2F1, reactivation 
of PP2A, a decrease in BCR-ABL tyrosine kinase activity and reduced cellular proliferation. 
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METHODS 
Patient cohort 
The study was approved by the Liverpool Central Research Ethics Committee; all 74 patients gave 
informed consent and were aged 18 or over. All have been seen since original diagnosis of chronic 
phase CML at our centre and have been followed for at least 9 months (median follow-up: 50 months). 
Patient characteristics are shown in Table 1. Patients were diagnosed between 2005-2013 and we 
include all patients who progressed during this time.  
 
Sample Collection and Preparation 
At diagnosis and after 1 month of TKI treatment, mononuclear cells (MNC) from chronic phase CML 
patients were separated by density-dependent centrifugation (Lymphoprep Axis-Shield, Norway), 
washed in RPMI 1640 (BioSera, UK), and resuspended in 10% DMSO/10% FCS (BioSera), /RPMI at 4°C. 
Wherever possible, samples were enriched for CD34+ cells using the CliniMACS kit (Miltenyi Biotec, 
USA).  
 
Measurement of CIP2A, PP2Ac, phosphorylated PP2A, c-Myc and E2F1.  
Flow cytometry methodology has been previously described5, 36 and was used for the detection of 
PP2Ac, PP2AY307, CIP2A, c-Myc, c-MycS62, E2F1 and E2F1S364. The following antibodies were used: Anti-
PP2A catalytic subunit (Merck Millipore, UK), PP2AY307 (Epitomics, USA), CIP2A, E2F1 and E2F1S364 
(Santa Cruz Biotechnology, USA), c-Myc (New England Biolabs, UK), c-MycS62 (Abcam, UK), anti-mouse 
and anti-rabbit Alex fluor 488 (Invitrogen, UK). Levels of pCrKL and CrKL were used as an assay of BCR-
ABL1 activity, measured by flow cytometry as previously described.36 Supplementary information is 
available at Leukemia's website. 
 
CIP2A status  
CIP2A protein level was assessed by flow cytometry as described above and previously.5 In this study 
the diagnostic CIP2A protein level (mean fluorescence intensity (MFI)) for all 74 patients was 
calculated (supplementary Table 1). This range was 0-52, the interquartile range was 0.48 – 8.65, the 
median was 2.85 and the mean was 6.5. High CIP2A patients are defined as those patients with a CIP2A 
level greater than or equal to 7.3. The cut-off value was derived using receiver operating 
characteristics (ROC) curve analysis for the prediction of BC based on the diagnostic CIP2A protein 
level; minimisation of the Euclidian distance between the ROC curve and the corner (0, 1) was the 
criterion used. The optimal cut-off value produced an AUCROC = 0.902 (95% CI: 0.832, 0.973).  
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c-Myc protein and phosphorylation status  
Briefly, whole-cell lysates were prepared from MNC using NP40 lysis buffer as previously described.5 
 
In-vitro TKI or PP2A activation assay 
The effect of TKIs or PP2A activation was examined using MNC at a density of 2 x 106/ml were cultured 
either untreated or with 5μM imatinib or 150nM dasatinib or 5µM nilotinib, or 2.5µM FTY720 for 24 
hours.  
 
PP2A activity assay 
PP2A phosphatase assays were carried out using the PP2A IP phosphatase assay kit (Millipore). An 
optimised manufacturer’s protocol for this assay was kindly provided by Professor Danilo Perrotti, 
University of Maryland, Maryland, USA. 
 
small interfering RNA (siRNA) treatment. 
K562 or CD34+ cells were transfected using Nucleofector Kit V (Lonza, Switzerland) using the Amaxa 
instrument. After nucleofection cells were cultured for 72 hours prior to analysis. The following siRNAs 
were used: Control siRNA, CIP2A, and E2F1 (Santa Cruz Biotechnology, USA), c-Myc siRNA (Thermo 
Scientific, USA). 
 
CIP2A overexpression 
K562 cells were transfected using pCMV6AC-CIP2A-GFP or pCMV6AC-GFP (OriGene, USA) as a control, 
using the Nucleofector Kit V (Lonza, Switzerland) using the Amaxa instrument.  After nucleofection 
cells were cultured for 72 hours prior to analysis.  
 
Measurement of bromodeoxyuridine (BrdU) incorporation 
Cellular proliferation was assessed using a BrdU cell proliferation ELISA (Roche Diagnostics, UK). 
Briefly, 1x105 cells were incubated with BrdU for 24h. Cells were then fixed and DNA denatured, anti-
BrdU-POD antibody was added, cells washed and incubated with TMB. The reaction was stopped by 
addition of sulphuric acid. The plate was read at 450nm. 
 
Statistical Analysis 
Statistical analysis and comparisons were performed using the statistical programmes SPSS 16.0 (SPSS 
Inc. USA) and R (R Core Team 2013, Austria). Continuous variables were summarised by descriptive 
statistics (median, IQR, range) while frequencies and percentages were calculated for categorical data. 
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For continuous variables, the Mann-Whitney U test was used for comparisons between independent 
samples and the Wilcoxon signed-rank test was used for paired data; for categorical variables Fisher’s 
exact test was used. Overall and progression-free survival functions were estimated by the Kaplan-
Meier estimator and the log-rank test was used for comparisons between groups. Cumulative 
incidence functions adjusted for the competing risk of death/ progression were estimated for Time to 
CCR, MMR and MR4 and differences across groups were assessed using Gray’s test. All tests were two-
sided at a 5% significance level. No adjustment for multiple testing was performed while no missing 
data imputation was required since the analysed dataset was complete.   
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RESULTS 
High CIP2A expressing patients do not progress to blast crisis if treated with 2G TKI from initial 
diagnosis. 
At diagnosis of chronic phase CML, CIP2A protein levels were assessed by flow cytometry 5 in 74 
patients. Patients were stratified into high (>7.3 MFI) and low CIP2A (<7.3 MFI) groups according to 
their diagnostic level, as defined in the methodology. 
 
For patients with high diagnostic CIP2A level treated with imatinib, the overall and progression-free 
survival probability at 24 months was estimated to be 41% (95% CI: 6% - 75%) and 17% (95% CI: 1% - 
51%) respectively, compared to 100% for patients in any other group (p<0.001, Figure 1). Disease 
progression to BC only occurred in those patients with a high diagnostic level of CIP2A and treated 
with imatinib. All progressions occurred within 32 months from diagnosis with the median time to 
progression being 12.5 months (IQR: 10.3 - 20.15). Progression was not associated with the 
development of BCR-ABL kinase domain mutations.  
 
The estimated cumulative incidence functions of complete cytogenetic response (cumulative CCR 
rate) is presented in Figure 2A; for low CIP2A level imatinib treated patients at 18 months was 85% 
(95% CI: 70%-95%). Only one patient with a high diagnostic CIP2A level and treated with imatinib 
achieved a CCR (p<0.001); this patient subsequently progressed. Again, this deleterious effect of high 
CIP2A was not seen if patients were treated with a 2G TKI from diagnosis, where the estimated 
cumulative CCR rate at 18 months was 86% (95% CI: 68%-96%) and 56% (28%-86%) for the low and 
high CIP2A 2G TKI patients respectively. A similar trend was observed in time to major molecular 
response (MMR), as shown in Figure 2B.  
 
The cumulative rate of MR4 (BCR-ABL1 transcript level of ≤0.01%) for low CIP2A imatinib treated 
patients was 16% (95% CI: 7-34%) at 18 months. No patient with a high diagnostic CIP2A level and 
treated with imatinib achieved MR4 (p=0.008, Figure 2C). High CIP2A patients treated with a 2G TKI 
have a lower rate of MR4 compared to the low CIP2A 2G TKI treated patients, at 11% and 48% at 18 
months respectively. High diagnostic CIP2A levels in patients treated with a 2G TKI predict for poor 
molecular response (p=0.019).  
 
Early molecular response (EMR, BCR-ABL1/ABL1 ratio of <10% at 3 months) is an excellent predictor 
of clinical outcome in imatinib treated patients.37-39 55% of imatinib treated low CIP2A patients 
achieved an EMR, compared to only 9% of high CIP2A patients (p=0.01 Figure 2D). 90% of low CIP2A 
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patients treated with a 2G TKI achieved an EMR compared to 44% of those with a high CIP2A level. 
These data demonstrate that patients with high CIP2A and treated with a 2G TKI have a higher rate of 
achieving an EMR. In summary, patients with high diagnostic CIP2A levels and treated with a 2G TKI at 
initial diagnosis do not progress to BC and have a similar clinical outcome to low CIP2A patients.  
 
 
2G TKIs but not imatinib suppress the CIP2A pathway. 
We investigated if the superior clinical outcome in the high CIP2A 2G TKI cohort could be explained by 
the 2G TKIs modulating the CIP2A pathway. MNC from 20 newly diagnosed chronic phase CML patients 
were treated with the three TKIs for 24 hours in an in vitro assay. CIP2A levels significantly decreased 
in high CIP2A patients following dasatinib or nilotinib treatment (p=0.007 and p=0.001 respectively), 
but imatinib had no significant effect (Figure 3A). This 2G TKI associated decrease in CIP2A was 
accompanied by a significant decrease in c-Myc following dasatinib and nilotinib treatment (p=0.002, 
Figure 3B). All three TKIs decreased c-Myc and c-MycS62 levels compared to untreated control; 
however dasatinib and nilotinib also caused a significant decrease beyond that achieved with imatinib 
(p=0.03 and p=0.008 for c-Myc and p=0.01 and p=0.008 c-MycS62).  
 
PP2A activity can readily be assessed using two methods. PP2A is inactive when it is phosphorylated 
at Y307, and levels of PP2AY307 phosphorylation can be measured by flow cytometry. PP2A activity assay 
can also be assessed directly, though this requires many cells; where cell availability was restricted the 
flow cytometry approach was used. Supplementary Figure 1 shows the correlation between PP2A 
activity assay and flow cytometry assessment of PP2AY307.  
 
In vitro TKI treatment of cells from high CIP2A patients resulted in a  decrease in PP2AY307 
phosphorylation and hence increased PP2A  and this activity was only observed in dasatinib (p=0.03) 
and nilotinib treated cells (p=0.04) and not with imatinib. This is consistent with our earlier  in vivo 
observation that PP2AY307 is not reduced following 12 months of imatinib treatment in high CIP2A 
patients.5 In line with this, Figure 3K shows that in high CIP2A expressing K562 cells, there is a trend 
for 2G TKIs to increase PP2A activity to a greater degree than imatinib. Figure 3E and J demonstrate 
that these differences in TKI effects are not mediated by differential suppression of BCR-ABL activity 
(as assessed using the pCrKL assay,36,40,41), since all three TKIs suppress the pCrKL/CrKL ratio to a similar 
degree. The differences observed were not attributable to changes in viability (Supplementary Figure 
2). 
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The TKIs had no effect on CIP2A or c-Myc in patients with a low diagnostic CIP2A level. PP2A activity 
increased (demonstrated by decreased PP2AY307 Figure 3I); suggesting PP2A inhibition occurs by 
another mechanism, possibly involving SET.4, 5  
 
E2F1 acts like a control switch in the CIP2A pathway. 
Laine et al8 recently demonstrated that in breast cancer, a p53-mediated  increase in E2F1 leads to 
the up-regulation of CIP2A. In CML, p53 mutations only occur in about 15-20% of patients in BC and 
are rarely observed at diagnosis.42-44  No patient with a high diagnostic CIP2A level had a 17p deletion 
or rearrangement, although the TP53 gene was not sequenced to unequivocally determine a 
mutation. E2F1 has previously been shown to be over-expressed in CML.27  E2F1 was significantly 
higher in CML MNC compared to normal MNC (p=0.02). E2F1 is high in patients with high diagnostic 
CIP2A protein levels compared to those with low CIP2A protein levels (p=0.04, Figure 4A). In high 
CIP2A patients, following 1 month of clinical 2G TKI treatment, E2F1 protein levels significantly 
decreased (p=0.01, Figure 4B) and this was accompanied by a decrease in mRNA levels of its 
transcriptional target CIP2A (Figure 4C). In sharp contrast, imatinib did not suppress E2F1, and thus 
CIP2A mRNA levels remain unchanged. Furthermore, no difference in BCR-ABL1 mRNA expression was 
observed after one month of imatinib or 2G TKI treated patients. 
 
E2F1 is stabilised by phosphorylation at S364 and PP2A can regulate E2F1 by controlling its 
phosphorylation status.8  To investigate whether E2F1 is stabilised in patients with high CIP2A protein 
as a consequence of impaired PP2A function, K562 cells were treated with the PP2A activator FTY720. 
FTY720 activates PP2A by binding and sequestering SET from PP2Ac.22, 45-47 FTY720 increased PP2A 
activity (p=0.009, Figure 4D) and decreased CIP2A (p=0.01, Figure 4E). FTY720 reactivation of PP2A 
resulted in a decrease in E2F1S364 (p=0.04, Figure 4F) leading to a decrease in total E2F1 protein 
(p=0.01, Figure 4G). These data imply that CIP2A acts to inhibit PP2A leading to stabilisation of E2F1, 
creating a positive feedback loop generating constant transcription and stabilisation of both CIP2A 
and c-Myc. This model is summarised in Figure 4H. 
  
This putative positive feedback loop was interrogated by sequentially depleting CIP2A, c-Myc and E2F1 
in K562 cells (Supplementary Figure 3). Inhibition of CIP2A reduced both c-Myc (p=0.002) and E2F1 
(p=0.004). A decrease in BCR-ABL tyrosine kinase activity was also noted (data not shown). c-Myc 
inhibition resulted in a decrease in CIP2A (p=0.03) and E2F1 (p=0.003); again a decrease in BCR-ABL 
tyrosine kinase activity was observed. Finally E2F1 was inhibited and this caused a decrease in both 
CIP2A (p=0.004) and c-Myc (p=0.003). These data support our model in Figure 4H that a positive 
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feedback loop exists between CIP2A/c-Myc and E2F1. We next repeated the siRNA experiments using 
CD34+ selected CML cells from high CIP2A patients (Figure 5). Depleting CIP2A in CD34+ cells results 
in the reactivation of PP2A resulting in the dephosphorylation of E2F1; thus a decrease in E2F1 and c-
Myc. This may occur by two mechanisms; firstly the decrease in CIP2A level means that CIP2A can no 
longer stabilise c-Myc, and secondly the reduction in E2F1 removes its drive to transcribe c-Myc 
(Figure 5A-C). In CD34+ cells, c-Myc knockdown resulted in a decrease in CIP2A (p=0.04) and E2F1 
(p=0.04, Figure 5D-F). This is consistent with our model (Figure 4H), whereby decreased CIP2A will 
reactivate PP2A, leading to the dephosphorylation of E2F1 and therefore a decrease in E2F1.  Finally 
E2F1 was depleted in CD34+ cells. This resulted in a decrease in CIP2A (p=0.002) and c-Myc (Figure 
5G-I).  
 
Taken together, these data suggest that the E2F1 level is a major factor regulating the CIP2A/c-Myc 
pathway, whereby the CIP2A/c-Myc complex inhibits PP2A activity and thus E2F1 remains 
phosphorylated at S364 thereby creating a positive feedback loop. The 2G TKIs but not imatinib reduce 
E2F1, which is controlling the CIP2A/c-Myc pathway. This explains the clinical observation of Figures 
1 and 2 that patients with high diagnostic CIP2A level do not progress to BC if treated with a 2G TKI as 
the CIP2A/c-Myc/E2F1 pathway is suppressed. 
 
 
 
CIP2A alters cellular proliferation rates  
c-Myc and E2F1 have well documented effects on proliferation, and CIP2A overexpression in  neural 
progenitor cells increases  proliferation.48 We next examined whether high levels of CIP2A affected 
the rate of proliferation in CML. Inhibition of CIP2A in K562 cells by siRNA (transfection efficiency 50%) 
resulted in a 20% decrease in cellular proliferation (p=0.02, Figure 6A). Conversely, when CIP2A was 
over-expressed using pCMV6AC-CIP2A-GFP plasmid (transfection efficiency 70%), a 35% increase in 
the rate of proliferation was seen (p=0.02, Figure 6B). To determine if the reduction in proliferation 
observed when CIP2A was inhibited was a result of PP2A reactivation, K562 cells were treated with 
the PP2A activator FTY720. FTY720 treatment reduced the rate of proliferation (p=0.02, Figure 6C). 
Figure 6D shows that all three TKIs significantly inhibit proliferation, to a similar degree, in 
unmanipulated K562 cells. However, in K562 cells overexpressing CIP2A (by transfection of pCMV6-
CIP2A-GFP plasmid), imatinib treatment did not alter proliferation, whereas dasatinib and nilotinib 
both reduced proliferation (p=0.03 and p=0.03 respectively, Figure 6E). This again demonstrates a 
differential effect on CIP2A between imatinib versus 2G TKI. 
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DISCUSSION 
The early identification of CML patients likely to progress and die from BC is important. CIP2A has 
previously been identified as a biomarker which identifies those patients likely to progress into BC, if 
treated with imatinib.5 Here, we extend these observations, showing that patients with a high 
diagnostic CIP2A level and treated with a 2G TKI do not progress to BC, unlike those treated with 
imatinib. The survival and molecular outcomes of those patients with a high CIP2A level at diagnosis 
and treated with a 2G TKI are similar to those with a low CIP2A diagnostic level, although high CIP2A 
patients treated with a 2G TKI have an inferior MR4 rate than low CIP2A patients, suggesting that high 
CIP2A in 2G TKI treated patients is a marker for poor molecular response.  
 
Both dasatinib and nilotinib significantly decrease CIP2A levels in primary CML cells, and this is 
associated with a decrease in both c-Myc and BCR-ABL tyrosine kinase activity, and reactivation of 
PP2A. Imatinib did reduce the BCR-ABL tyrosine kinase activity, it did not affect CIP2A levels nor did it 
significantly reactivate PP2A.  
 
The present data are consistent with a positive feedback loop within the CIP2A/c-Myc/E2F1 pathway 
(Figure 4H). E2F1 is significantly higher in patients with a high diagnostic CIP2A level; this is a likely 
consequence of PP2A inactivation. Reactivation of PP2A by FTY720 decreases E2F1 levels.  In high 
CIP2A patients, CIP2A stabilises c-Myc and inactivates PP2A. When PP2A is inactivated it is no longer 
able to dephosphorylate E2F1 thus E2F1 remains stabilised, whereby it transcriptionally activates both 
CIP2A and c-Myc which sustains PP2A inactivation via a positive feedback loop. Active PP2A can cause 
the proteasomal degradation of non-phosphorylated BCR-ABL by activating SHP1.4 SHP1 down-
regulation is associated with disease progression.49 If PP2A is inactivated by CIP2A then it will no longer 
be able to activate SHP1 and thus BCR-ABL remains phosphorylated and active. We have shown that 
FTY720 reduces CIP2A, but since FTY720 is also known to inhibit the PP2A-SET interaction45-47 it is likely 
that both CIP2A and SET play a role in PP2A inhibition in CML. 
 
Our study highlights a role for E2F1 in the CIP2A pathway, and others have shown that E2F1 is a target 
of BCR-ABL kinase activity and might have a role in BCR-ABL leukaemogenesis in vitro.29, 50  Moreover, 
it cannot be assumed that E2F1 is the only transcription factor regulating CIP2A and others may 
influence this dynamic process. Furthermore, the role of E2F1 is complex, as there is a degree of 
redundancy between the family members and other members of the E2F family such as E2F3 have 
been shown to play a role in CML BC.51  Although loss of E2F1 is generally associated with a decrease 
in proliferation, one study has shown that impaired DNA replication of haematopoietic progenitors in 
Lucas CM et al   CIP2A/c-Myc/E2F1 pathway in CML 
 
14 
 
E2F1/E2F2 mutant mice allows BCR-ABL expressing progenitors to outcompete non-mutated cells, 
promoting leukaemogenesis.52 Thus, CIP2A remains an attractive therapeutic target since high levels 
are only found in malignant cells. 
 
Using both K562 and CML CD34+ cells we demonstrate that inhibition of CIP2A decreases c-Myc and 
reactivates PP2A, resulting in a reduction in E2F1 levels. c-Myc inhibition decreases CIP2A and 
reactivates PP2A, again leading to a decrease in E2F1. Furthermore we have recently demonstrated 
that c-Myc inhibition the small molecule inhibitor 10058-F4 leads to a reduction in both CIP2A and 
BCR-ABL tyrosine kinase activity.53 Moreover, E2F1 inhibition results in a decrease in both CIP2A and 
c-Myc. These data suggest that disruption of the CIP2A/c-Myc/E2F1 interaction is important for the 
reactivation of PP2A and suppression of BCR-ABL.  
 
CIP2A is known to stabilise c-Myc. c-Myc plays a critical role in proliferation and cell cycle, and levels 
are elevated in those patients with a high diagnostic CIP2A level.5 E2F1 results in uncontrolled cellular 
proliferation.30  CIP2A has been shown to be involved in cell cycle progression through chromosome 
separation and mitotic spindle dynamics,54 supporting the notion that CIP2A plays a role in 
proliferation. Here we have shown that CIP2A, c-Myc and E2F1 interact and regulate each other. 
Inhibition of CIP2A reduces and overexpression increases proliferation, suggesting that patients with 
a high diagnostic CIP2A level potentially have cells which will proliferate faster. Importantly, we show 
that 2G TKIs but not imatinib reduce proliferation when CIP2A is overexpressed.  
 
In those patients with a low diagnostic level of CIP2A, imatinib treatment can suppress both BCR-ABL 
and SET, and this leads to a degree of PP2A reactivation allowing SHP1 to dephosphorylate BCR-ABL. 
In patients with high prevailing CIP2A levels, their PP2A activity is suppressed to a much greater degree 
by both CIP2A and SET and imatinib is unable to relieve this suppression. 2G TKIs can suppress CIP2A 
and E2F1, leading to reactivation of PP2A and suppression of BCR-ABL. Moreover, we show that E2F1 
is elevated in high CIP2A patients and this is reduced by 2G TKIs but not imatinib. We speculate that 
PP2A inactivation may be the key event. When BCR-ABL is inhibited with a TKI, PP2A is reactivated, 
and E2F1 and CIP2A are reduced. If CIP2A is inhibited by siRNA, then again PP2A is reactivated leading 
to a reduction in E2F1 and BCR-ABL.   
 
In conclusion, our study highlights the importance of CIP2A/c-Myc/E2F1 pathway in CML. A patient 
with a high diagnostic CIP2A level is far less likely to progress to BC if treated with a 2G TKI from original 
diagnosis, because the 2G TKIs modulate the CIP2A/c-Myc/E2F1 pathway. Overall, these data suggest 
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that if a patient has a high CIP2A level at diagnosis then they should not be treated with imatinib due 
to the high risk of disease progression; these patients should be offered either dasatinib or nilotinib 
upfront. There is therefore now a case for routine CIP2A testing at diagnosis. Further study to 
determine the true incidence of high CIP2A patients in the general CML population is needed. A 
multivariate analysis of a bigger cohort is also required to establish relationships between the high 
level of CIP2A and other factors in predicting response to these TKIs and clinical outcome in CML. 
  
Supplementary information is available at Leukemia's website. 
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FIGURE LEGENDS 
Table 1. Patient characteristics. 
 
Figure 1. High CIP2A expressing patients do not progress if treated with a second generation TKI. 
All 74 patients involved in the study are included in the Kaplan-Meier estimates of overall survival and 
progression free survival plots.  Panel A. Overall survival, Panel B. Progression-free survival, the 
number of assessable cases are shown below each plot and the survival probability along with 
confidence internals (CI) are shown in the table directly below each plot. The Log rank test was used.  
 
Figure 2. High CIP2A expressing patients can achieve a deep molecular response if treated with a 
second generation TKI. 
Cumulative Incidence functions for time to CCR, MMR and MR4 adjusted for the competing risk of 
death/progression. All 74 patients involved in the study are included in the analysis.  Panel A. Time to 
CCR, Panel B. Time to MMR, Panel C. Time to MR4 and the number of assessable cases are shown 
below each plot and the probability of achieving CCR, MMR and MR4 along with confidence internals 
(CI) are shown in the table directly below each plot. Gray's test was used to analyse panels A-C   and 
Fisher’s exact test in panel C. 
 
 
Figure 3. 2G TKIs decrease CIP2A and c-Myc with reactivation of PP2A. 
MNC from chronic phase newly diagnosed CML patients were treated with 5μM imatinib, 150nM 
dasatinib or 5μM nilotinib for 24 hours. Patients were stratified into high CIP2A (left hand side of the 
Figure) and low CIP2A (right hand side of the Figure). Panel A show the effects of TKIs on CIP2A protein 
as assessed by flow cytometry. Panels B and C, show the effect on c-Myc and c-MycS62 levels expressed 
as absorbance units by an ELISA.  Panel D,  the effect on PP2AY307 protein level assessed by flow 
cytometry. Panel E the effect on BCR-ABL tyrosine kinase activity, determined using the pCrKL/CrKL 
ratio assessed by flow cytometry (n=20 total, low CIP2A n=9 and high CIP2A n=11). p values in each 
case relate to the comparison with untreated control.; for comparison of imatinib  vs 2G TKI see text. 
Statistical analysis was calculated using Mann-Whitney test.  Panel F shows the effects on PP2A activity 
in K562 cells. Error bars are standard error of mean (SEM) 
 
 
Figure 4. The transcription factor E2F1 is elevated in high CIP2A patients and is suppressed by 2G 
TKIs but not imatinib.  
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Panel A. E2F1 levels were assessed by flow cytometry using diagnostic chronic phase MNC from low 
and high CIP2A patients (n=21).  Panel B. E2F1 levels in high CIP2A patients at diagnosis and following 
1 month of clinical imatinib (n=5) or 2G TKI treatment (n=5). Panel C. CIP2A mRNA expression 
decreases following 24 hour treatment with 2G TKI but not imatinib (n=18).  Panel D. effects of 24 
hours treatment with the PP2A activator 2.5µM FTY720 on PP2A activity in K562 cells (n=7). Panel E. 
CIP2A protein following treatment with 2.5µM FTY720 (n=10). Panel F-G. FTY720 treatment decreases 
both E2F1 and E2F1S364 in K562 cells (n=6). All values in the panels are means -/+ standard error of 
mean (SEM).Panel H. A suggested model for the CIP2A/c-Myc/E2F1 pathway. Arrows denote 
activation, blunt ended arrows indicated inhibition. Phosphorylated E2F1 can transcribe both CIP2A 
and c-Myc, which stabilise each other and cause PP2A inhibition. Inactive PP2A cannot 
dephosphorylate E2F1 and thus E2F1 remains active; creating a positive feedback loop. Statistical 
analysis was performed using Mann-Whitney test.  
 
Figure 5. Inhibition of CIP2A, c-Myc and E2F1 in CD34+ cells 
CD34+ selected CML cells from five patients were treated with each siRNA for 72 hours prior to 
analysis.  With CIP2A siRNA a decrease in CIP2A, c-Myc and E2F1 was observed (panels  A-C). With c-
Myc siRNA a decrease in CIP2A, c-Myc and E2F1 was observed (panels D-F). With E2F1 siRNA a 
decrease in CIP2A, c-Myc and E2F1 was observed (panels G-I). Statistical analysis was performed using 
Mann-Whitney test. Error bars are standard error of mean (SEM). 
 
Figure 6. CIP2A alters the rate of proliferation 
The effects of CIP2A and TKI treatment on proliferation rate was assessed in K562 cells using a BrdU 
assay each assay was performed in triplicate and the experiment was perform a minimum of three 
times. Panel A. Inhibition of CIP2A decreases proliferation (n=4). Panel B. Overexpression of CIP2A 
using the pCMV8-CIP2A-GFP plasmid increases proliferation (n=5). Panel C. FTY720 reduces 
proliferation (n=4). Panel D. All three TKIs reduce proliferation rates significantly (n=4). Panel E. CIP2A 
was over expressed using the pCMV8-CIP2A-GFP and subsequently treated with imatinib, dasatinib 
and nilotinib. Only dasatinib and nilotinib reduced the rate of proliferation (n=5). Statistical analysis 
was performed using Mann-Whitney test. Error bars are standard error of mean (SEM) 
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Supplementary methods 
Measurement of  CIP2A, PP2Ac, phosphorylated PP2A, c-Myc and E2F1.  
Flow cytometry methodology has been previously described1, 2 and was used for the detection of 
PP2Ac, PP2A Y307, CIP2A, c-Myc, c-Myc S62, E2F1 and E2F1 S364.  Briefly, cells (~1x105) were fixed by 
resuspending in 500μl of 2% paraformaldehyde at pH 7.2 (VWR, UK) for 10 minutes at 37°C and then 
centrifuged at 770g for 3 minutes. 500μl of 90% methanol (Fisher Scientific, UK) was added to the cell 
pellet and the cells were vortexed and then incubated on ice for 30 minutes. Cells were then washed 
(throughout with 1ml incubation buffer containing PBS and 0.5% bovine serum albumin (BSA) (Sigma-
Aldrich)), and centrifuged at 770g for 3 minutes. Cells were resuspended in 25μl incubation buffer. 
Appropriate antibody and controls were added Anti-PP2A catalytic subunit (Merck Millipore,  UK), 
PP2A Y307 (Epitomics, USA),  CIP2A, E2F1 and E2F1 S364 (Santa Cruz Biotechnology, USA), c-Myc (New 
England Biolabs, UK), c-Myc S62 (Abcam, UK), anti-mouse and anti-rabbit Alex fluor 488 (Invitrogen, 
UK). Mouse IgG (BD, UK) and normal rabbit IgG (R&D systems, UK) were used as controls Cells were 
vortexed and incubated at room temperature for 40 minutes. Cells were then washed twice and 
resuspended in 100μl incubation buffer containing 10µg/ml goat anti rabbit/mouse second Alexa 
Fluor 488 antibody (Invitrogen), incubated at room temperature in the dark for 30 minutes, then 
washed twice and analysed using flow cytometry (FACScalibur), with Cellquest Pro software (BD) for 
data analysis. The mean fluorescence intensity (MFI) of the protein was determined as the MFI for the 
given protein minus that of the appropriate control. Levels of pCrKL and CrKL were used as an assay 
of BCR-ABL activity, measured by flow cytometry as previously described.2  
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